Evaluating natalizumab first-line and later-line use in multiple sclerosis: a US claims database analysis
Natalizumab as a first-line treatment was associated with greater reductions in ARR and MS-related HCRU compared to later-line use.
Authors
- Robin L. Avila
- Jason C. Simeone (ORCID: https://orcid.org/0000-0002-6141-8043)
- Nicole S. Croteau
- Khalil Jomaa
- Fei Tang
- Mattia Gianinazzi
- Boyang Bian (ORCID: https://orcid.org/0000-0003-0153-4218)
Institutions
- Biogen (United States) (US)
- Biogen (Switzerland) (CH)
- Access to Wholistic and Productive Living Institute (US)
- Cytel (United States) (US)
Publication Details
- Journal
- Therapeutic Advances in Neurological Disorders
- Published
- 2025-03-17
- DOI
- https://doi.org/10.1177/17562864251317949
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Biogen